{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:29:56Z","timestamp":1793366996231,"version":"4.5.0"},"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Economic Development and Innovation Operative Programme","award":["GINOP 2.3.2-15-2016-00048"],"award-info":[{"award-number":["GINOP 2.3.2-15-2016-00048"]}]},{"name":"Human Resources Development Operational Programme","award":["EFOP-3.6.2-16-2017-00006"],"award-info":[{"award-number":["EFOP-3.6.2-16-2017-00006"]}]},{"name":"New National Excellence Programme, Ministry of Human Capacities","award":["\u00daNKP-19-3-I"],"award-info":[{"award-number":["\u00daNKP-19-3-I"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The introduction of tyrosine kinase inhibitors (TKIs) has revolutionized the therapy of chronic myeloid leukemia (CML). Although the efficacy of TKIs is beyond dispute, conception-related safety issues are still waiting to be explored, particularly in males. This systematic review aimed to summarize all available evidence on pregnancy outcomes of female spouses of male CML patients who fathered children after TKI treatment for CML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic search in seven electronic databases for studies that reported on male CML patients who did or did not discontinue TKI treatment before conceiving, and the pregnancy outcomes of their female spouse are available. The search centered on the TKI era (from 2001 onward) without any other language or study design restrictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of a total of 38 potentially eligible papers, 27 non-overlapping study cohorts were analyzed. All were descriptive studies (case or case series studies). Altogether, 428 pregnancies from 374 fathers conceived without treatment discontinuation, 400 of which (93.5%) ended up in a live birth. A total of ten offspring with a malformation (2.5%) were reported: six with imatinib (of 313 live births, 1.9%), two with nilotinib (of 26 live births, 7.7%), one with dasatinib (of 43 live births, 2.3%), and none with bosutinib (of 12 live births). Data on CML status were scarcely reported. Only nine pregnancies (from nine males) and no malformation were reported in males who discontinued TKI treatment before conception.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Malformations affected, on average 2.5% of live births from fathers who did not discontinue TKI treatment before conception, which is comparable with the rate of malformations in the general population. Large-scale studies with representative samples are awaited to confirm our results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0243045","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T14:24:51Z","timestamp":1607005491000},"page":"e0243045","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A systematic review"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7035-941X","authenticated-orcid":true,"given":"Zsolt","family":"Szak\u00e1cs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6443-0259","authenticated-orcid":true,"given":"P\u00e9ter Jen\u0151","family":"Hegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelli","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rta","family":"Balask\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienn","family":"Er\u0151s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szabina","family":"Szuj\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Pammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett","family":"Mosd\u00f3si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4358-9834","authenticated-orcid":true,"given":"M\u00e1ria","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3749-6444","authenticated-orcid":true,"given":"Gabriella","family":"F\u00fcr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alizadeh","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"issue":"Suppl 2","key":"pone.0243045.ref001","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"M Hoglund","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"pone.0243045.ref002","doi-asserted-by":"crossref","first-page":"e004266","DOI":"10.1136\/bmjopen-2013-004266","article-title":"Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort","volume":"4","author":"AG Smith","year":"2014","journal-title":"BMJ Open"},{"issue":"3","key":"pone.0243045.ref003","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canep.2013.01.002","article-title":"Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries","volume":"37","author":"AM Mendizabal","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"10","key":"pone.0243045.ref004","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"A Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0243045.ref005","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"R Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"pone.0243045.ref006","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"R Capdeville","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"pone.0243045.ref007","first-page":"357027","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"N Iqbal","year":"2014","journal-title":"Chemother Res Pract"},{"key":"pone.0243045.ref008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2018.08.016","article-title":"Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis","volume":"104","author":"MM Fachi","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"pone.0243045.ref009","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2162-3619-2-5","article-title":"The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis","volume":"2","author":"S Mealing","year":"2013","journal-title":"Exp Hematol Oncol"},{"issue":"21","key":"pone.0243045.ref010","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1806.1806","article-title":"Gimema registry of conception\/pregnancy in adult patients diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)","volume":"124","author":"E Abruzzese","year":"2014","journal-title":"Blood"},{"issue":"8","key":"pone.0243045.ref011","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","article-title":"Management of pregnant chronic myeloid leukemia patients","volume":"9","author":"E Abruzzese","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"Suppl 2","key":"pone.0243045.ref012","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1007\/s00277-015-2317-z","article-title":"Managing pregnancy in chronic myeloid leukaemia","volume":"94","author":"R Palani","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"pone.0243045.ref013","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1078155213500686","article-title":"Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report","volume":"20","author":"VS Ghalaut","year":"2014","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"pone.0243045.ref014","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2010.08.060","article-title":"Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty","volume":"95","author":"S Mariani","year":"2011","journal-title":"Fertil Steril"},{"issue":"20","key":"pone.0243045.ref015","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","article-title":"Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome","volume":"351","author":"T Seshadri","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0243045.ref016","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11523-017-0521-6","article-title":"Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase","volume":"12","author":"X Chang","year":"2017","journal-title":"Target Oncol"},{"issue":"2","key":"pone.0243045.ref017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/shem.2003.50038","article-title":"Imatinib treatment: specific issues related to safety, fertility, and pregnancy","volume":"40","author":"ML Hensley","year":"2003","journal-title":"Semin Hematol"},{"issue":"10","key":"pone.0243045.ref018","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.6004\/jnccn.2009.0069","article-title":"Issues of imatinib and pregnancy outcome","volume":"7","author":"J Apperley","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"pone.0243045.ref019","first-page":"1","article-title":"Management of chronic myelogenous leukemia in pregnancy","volume":"35","author":"A Bhandari","year":"2015","journal-title":"Anticancer Res"},{"issue":"5","key":"pone.0243045.ref020","first-page":"478","article-title":"Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?","volume":"103","author":"C Jovelet","year":"2016","journal-title":"Bull Cancer"},{"issue":"4","key":"pone.0243045.ref021","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2012-4085","article-title":"Clinical review: kinase inhibitors: adverse effects related to the endocrine system","volume":"98","author":"MB Lodish","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0243045.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.08.005","article-title":"Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue","volume":"107","author":"E Lorenzi","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"pone.0243045.ref023","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"D Moher","year":"2009","journal-title":"Annals of internal medicine"},{"issue":"2","key":"pone.0243045.ref024","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"MH Murad","year":"2018","journal-title":"BMJ evidence-based medicine"},{"issue":"15","key":"pone.0243045.ref025","doi-asserted-by":"crossref","first-page":"18031","DOI":"10.1200\/jco.2008.26.15_suppl.18031","article-title":"Fertility in patients on imatinib for chronic myeloid leukemia","volume":"26","author":"MK Siddique","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0243045.ref026","doi-asserted-by":"crossref","first-page":"e2014028","DOI":"10.4084\/mjhid.2014.028","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"E Abruzzese","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"pone.0243045.ref027","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2014.10.002","article-title":"Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre","volume":"39","author":"H Alizadeh","year":"2015","journal-title":"Leuk Res"},{"key":"pone.0243045.ref028","first-page":"130","article-title":"Management of chronic myeloid leukemia (CML) during pregnancy among patients (pts) treated with a tyrosine kinase inhibitor (TKI): A single-center experience","author":"R Assi","year":"2017","journal-title":"Blood"},{"issue":"7","key":"pone.0243045.ref029","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"P Ault","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0243045.ref030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/1658-5127.171987","article-title":"Outcome of young adults with chronic myeloid leukemia treated with upfront imatinib: A single institutional experience","volume":"6","author":"GK Babu","year":"2015","journal-title":"Journal of Applied Hematology"},{"issue":"3","key":"pone.0243045.ref031","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.leukres.2007.07.022","article-title":"Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases","volume":"32","author":"M Breccia","year":"2008","journal-title":"Leuk Res"},{"issue":"4","key":"pone.0243045.ref032","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00404-017-4321-0","article-title":"Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers (vol 295, pg 269, 2017)","volume":"295","author":"P Carlier","year":"2017","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"pone.0243045.ref033","first-page":"311","article-title":"Pregnancy outcomes and treatment regimens in patients with chronic myeloid leukemia","volume":"97","author":"E Chelysheva","year":"2012","journal-title":"Haematologica"},{"key":"pone.0243045.ref034","first-page":"294","article-title":"Pregnancy outcomes in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors","volume":"96","author":"E Chelysheva","year":"2011","journal-title":"Haematologica"},{"key":"pone.0243045.ref035","first-page":"262","article-title":"Pregnancy among the patients with chronic myeloid leukemia on imatinib therapy","volume":"94","author":"EY Chelysheva","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"pone.0243045.ref036","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V112.11.3230.3230","article-title":"Pregnancy Outcomes among Patients with Chronic Myeloid Leukemia Treated with Dasatinib","volume":"112","author":"J Cortes","year":"2008","journal-title":"Blood"},{"issue":"12","key":"pone.0243045.ref037","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.24186","article-title":"The impact of dasatinib on pregnancy outcomes","volume":"90","author":"JE Cortes","year":"2015","journal-title":"Am J Hematol"},{"key":"pone.0243045.ref038","first-page":"S844","article-title":"Report on imatinib treated CML patients: Pregnancy outcome","volume":"49","author":"S Dasgupta","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"3","key":"pone.0243045.ref039","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3109\/10428194.2013.811240","article-title":"Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib","volume":"55","author":"M Gentile","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"1\u20132","key":"pone.0243045.ref040","first-page":"90","article-title":"Successful pregnancies of spouses of male patients with chronic myeloid leukemia on imatinib therapy","volume":"46","author":"J Grudeva-Popova","year":"2010","journal-title":"Clinical and Transfusion Haematology"},{"key":"pone.0243045.ref041","first-page":"92","article-title":"Fertilit\u00e9, grossesse, allaitement et \u00e9tat de sant\u00e9 des nouveau-n\u00e9s chez les patient (e) s souffrant de LMC-PC et trait\u00e9 (e) s par inhibiteurs de la tyrosine kinase","volume":"6","author":"A Guerci-Bresler","year":"2011","journal-title":"Recommandations du groupe Fi-LMC Correspondances en Onco-h\u00e9matologie"},{"issue":"9","key":"pone.0243045.ref042","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3109\/10428194.2013.866662","article-title":"Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country","volume":"55","author":"J Iqbal","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"pone.0243045.ref043","first-page":"6","article-title":"Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors","volume":"33","author":"Q Jiang","year":"2012","journal-title":"Zhonghua xue ye xue za zhi"},{"key":"pone.0243045.ref044","first-page":"551","article-title":"Successful management of CML during pregnancy and in post-partum period","volume":"98","author":"H Klamov\u00e1","year":"2013","journal-title":"Haematologica"},{"key":"pone.0243045.ref045","first-page":"541","article-title":"Successful pregnancies in chronic myeloid Leukaemia male patients on imatinib therapy","volume":"95","author":"L Luciano","year":"2010","journal-title":"Haematologica"},{"key":"pone.0243045.ref046","first-page":"1","article-title":"Pregnancy Outcomes in Chronic Myeloid Leukemia: A Single Center Experience","volume":"5","author":"I Madabhavi","year":"2019","journal-title":"J Glob Oncol"},{"key":"pone.0243045.ref047","first-page":"40","article-title":"Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia (CML): Reports collected by the French regional pharmacovigilance (PV) centers","volume":"30","author":"M Markarian","year":"2016","journal-title":"Fundamental and Clinical Pharmacology"},{"key":"pone.0243045.ref048","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/ajcp\/aqx118.102","article-title":"Pregnancy outcomes in chronic myeloid leukemia (CML): A single-centre experience","volume":"149","author":"M Modi","year":"2018","journal-title":"American Journal of Clinical Pathology"},{"issue":"1","key":"pone.0243045.ref049","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11845-014-1084-5","article-title":"Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy","volume":"184","author":"A Mukhopadhyay","year":"2015","journal-title":"Ir J Med Sci"},{"issue":"1","key":"pone.0243045.ref050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00404-010-1501-6","article-title":"Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib","volume":"283","author":"H Oweini","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"pone.0243045.ref051","first-page":"168","article-title":"Conception of healthy childrens under imatinib treatment in two man affected by chronic myeloid leukemia","volume":"94","author":"M Pacilli","year":"2009","journal-title":"Haematologica"},{"issue":"4","key":"pone.0243045.ref052","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2141.2007.06542.x","article-title":"Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy","volume":"137","author":"K Ramasamy","year":"2007","journal-title":"Br J Haematol"},{"issue":"6","key":"pone.0243045.ref053","first-page":"887","article-title":"Clinical observation of fertility circumstance among patients with chronic granulocytic leukemia treated with imatinib","volume":"29","author":"G Ruirui","year":"2016","journal-title":"J Clin Hematol (China)"},{"issue":"5","key":"pone.0243045.ref054","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3109\/0284186X.2011.577562","article-title":"Fatherhood during imatinib","volume":"50","author":"E Shash","year":"2011","journal-title":"Acta Oncologica"},{"key":"pone.0243045.ref055","first-page":"555","article-title":"Pregnancies in patients with chronic myeloid leukemia treated with tysosine kinase inhibitors","volume":"98","author":"A Wang","year":"2013","journal-title":"Haematologica"},{"key":"pone.0243045.ref056","first-page":"690","article-title":"Impact of tyrosine kinase inhibitors (TKIs) on the fertility of chronic myeloid leukemia patients (CML) in a single center in Algeria","volume":"100","author":"B Yamina","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"pone.0243045.ref057","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.leukres.2013.07.020","article-title":"Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor","volume":"37","author":"L Zhou","year":"2013","journal-title":"Leuk Res"},{"issue":"1","key":"pone.0243045.ref058","first-page":"116","article-title":"One case report: a male patient with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies","volume":"10","author":"C Xiaohui","year":"2013","journal-title":"Zhong Guo Yi Yao Dao Bao"},{"issue":"12","key":"pone.0243045.ref059","first-page":"980","article-title":"Fertility and disease outcomes in patients with chronic myeloid leukemia","volume":"40","author":"XL Dou","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"2","key":"pone.0243045.ref060","doi-asserted-by":"crossref","first-page":"Ijh26","DOI":"10.2217\/ijh-2020-0004","article-title":"Pregnancy outcomes in patients treated with bosutinib","volume":"9","author":"JE Cortes","year":"2020","journal-title":"Int J Hematol Oncol"},{"issue":"5","key":"pone.0243045.ref061","first-page":"811","article-title":"Delivery of a Healthy Newborn by the Partner of a Patient with CML Undergoing Treatment with Nilotinib","volume":"47","author":"Y Aota","year":"2020","journal-title":"Gan To Kagaku Ryoho"},{"issue":"3\u20134","key":"pone.0243045.ref062","first-page":"1","article-title":"Environmental and individual exposure and the risk of congenital anomalies: a review of recent epidemiological evidence","volume":"42","author":"S Baldacci","year":"2018","journal-title":"Epidemiol Prev"},{"issue":"279","key":"pone.0243045.ref063","first-page":"1","article-title":"Trends in Infant Mortality in the United States, 2005\u20132014","author":"TJ Mathews","year":"2017","journal-title":"NCHS Data Brief"},{"key":"pone.0243045.ref064","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-90-481-9485-8_20","article-title":"The prevalence of congenital anomalies in Europe","volume":"686","author":"H Dolk","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"pone.0243045.ref065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/bdra.10012","article-title":"Guidelines for case classification for the National Birth Defects Prevention Study","volume":"67","author":"SA Rasmussen","year":"2003","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"9301","key":"pone.0243045.ref066","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(02)07373-7","article-title":"Descriptive studies: what they can and cannot do","volume":"359","author":"DA Grimes","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"pone.0243045.ref067","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"PB Burns","year":"2011","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"pone.0243045.ref068","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and outcome of 2904 CML patients from the EUTOS population-based registry","volume":"31","author":"VS Hoffmann","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"pone.0243045.ref069","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","article-title":"Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry","volume":"122","author":"M Hoglund","year":"2013","journal-title":"Blood"},{"issue":"2","key":"pone.0243045.ref070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","article-title":"Publication bias in meta-analysis: its causes and consequences","volume":"53","author":"A Thornton","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"pone.0243045.ref071","first-page":"2013","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","author":"JJ Gagnier","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"2","key":"pone.0243045.ref072","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/pds.4150","article-title":"A systematic review of pregnancy exposure registries: examination of protocol-specified pregnancy outcomes, target sample size, and comparator selection","volume":"26","author":"K Gelperin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T14:25:48Z","timestamp":1607005548000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243045"}},"subtitle":[],"editor":[{"given":"Ashkan","family":"Emadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":72,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0243045","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}